Immune globulin 10% - Octapharma

Drug Profile

Immune globulin 10% - Octapharma

Alternative Names: 10% high purity immunoglobulin; 10% IVIG; NewGam; octagam 10%; Octagam® Immune Globulin Intravenous (Human) 10% Liquid Preparation; Panzyga

Latest Information Update: 21 Apr 2017

Price : $50

At a glance

  • Originator Octapharma
  • Class Immunoglobulins; Immunoproteins; Serum globulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Immune thrombocytopenic purpura; Immunodeficiency disorders
  • Phase III Dermatomyositis
  • Phase II/III Chronic inflammatory demyelinating polyradiculoneuropathy
  • Discontinued Alzheimer's disease

Most Recent Events

  • 27 Feb 2017 Phase-III clinical trials in Dermatomyositis (Treatment-experienced) in USA, Czech Republic, Germany, Hungary (IV) (NCT02728752)
  • 30 Mar 2016 Octapharma plans the phase III ProDERM trial for Dermatomyositis in USA (IV) (NCT02728752)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top